Effects of Hazelnuts and Cocoa on Metabolic Parameters and Vascular Reactivity
Study Details
Study Description
Brief Summary
This study aims to assess the effects of hazelnuts, cocoa, and the combination of both on vascular reactivity and metabolic profile. Participants, divided in six groups, will receive one of these breakfast integrations for 14 days:
group 1) 30 g peeled hazelnuts;
group 2) 30 g unpeeled hazelnuts;
group 3) snack with 30 g peeled hazelnuts;
group 4) snack with 2.5 g cocoa powder;
group 5) snack with 30 g peeled hazelnuts and 2.5 g cocoa;
group 6) empty snack, control group.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
In the last few years, the prevalence of overweight and obesity has increased in all age groups. The European Food Safety Authority stated "cocoa flavanols help maintain endothelium-dependent vasodilation, which contributes to normal blood flow". Several studies reported that a daily consumption of hazelnuts reduces the risk of cardiovascular disease. The hypothesis of this study is to demonstrate a beneficial effect of hazelnut and cocoa diet integrations on vascular reactivity and endocrine-metabolic parameters.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 30g peeled hazelnuts cream Every person in this group will receive a 30 g peeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial. |
Dietary Supplement: Hazelnut
This dietary supplement contains 30 g of hazelnut.
Dietary Supplement: Cream
This dietary supplement is just a cream obtained by grinding hazelnuts.
|
Experimental: 30g unpeeled hazelnuts cream Every person in this group will receive a 30 g unpeeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial. |
Dietary Supplement: Hazelnut
This dietary supplement contains 30 g of hazelnut.
Dietary Supplement: Cream
This dietary supplement is just a cream obtained by grinding hazelnuts.
|
Experimental: snack w/ 30g peeled hazelnuts Every person in this group will receive a snack with 30 g peeled hazelnuts as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial. |
Dietary Supplement: Hazelnut
This dietary supplement contains 30 g of hazelnut.
Dietary Supplement: Snack
This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
|
Experimental: snack w/ 2.5g cocoa powder Every person in this group will receive a snack with 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial. |
Dietary Supplement: Cocoa
This dietary supplement contains 2.5 g of cocoa powder.
Dietary Supplement: Snack
This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
|
Experimental: snack w/ 30g peeled hazelnuts+2.5g cocoa Every person in this group will receive a snack with 30 g peeled hazelnuts and 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial. |
Dietary Supplement: Hazelnut
This dietary supplement contains 30 g of hazelnut.
Dietary Supplement: Cocoa
This dietary supplement contains 2.5 g of cocoa powder.
Dietary Supplement: Snack
This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
|
Placebo Comparator: empty snack Every person in this group will receive an empty snack as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial. |
Dietary Supplement: No hazelnuts / No cocoa
This dietary supplement does not contain hazelnut nor cocoa powder.
Dietary Supplement: Snack
This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
|
Outcome Measures
Primary Outcome Measures
- Effects of a breakfast integration on vascular reactivity, assessed by the variation of peak systolic velocity of the brachial artery, in healthy subjects. [2 weeks]
Vascular reactivity is measured by assessing the peak systolic velocity (PSV in cm/s) of the brachial artery at rest and after 3 minutes of arterial occlusion using an echographer in Doppler mode. To occlude arterial inflow, a sphygmomanometric cuff is placed above the antecubital fossa and inflated to at least 50 mmHg above systolic pressure for 3 minutes.
Secondary Outcome Measures
- Effects of a breakfast integration on total cholesterol (mg/dL) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on high-density lipoprotein-cholesterol (mg/dL) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on low-density lipoprotein-cholesterol (mg/dL) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on triglycerides (mg/dL) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on glucose (mg/dL) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on insulin (uU/mL) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on glucagon (pg/mL) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on leptin (ng/mL) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on ghrelin (ng/mL) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on uric acid (mg/dL) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on homocysteine (umol/L) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on ESR (mm/h) in healthy subjects. [2 weeks]
- Effects of a breakfast integration on hs-CRP (mg/dL) in healthy subjects. [2 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
- BMI 18.5-24.9 kg/m2
Exclusion Criteria:
-
diabetes mellitus
-
glucose intolerance
-
dyslipidemia
-
metabolic syndrome
-
allergies
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | San Donato Hospital | San Donato Milanese | Italy | 20097 |
Sponsors and Collaborators
- Ospedale San Donato
- Soremartec Italia S.r.l.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Nocciola/1